

**Patient Information** Fax completed form, insurance information and clinical documentation to 515.559.2495.

**Patient Name:** \_\_\_\_\_ **DOB:** \_\_\_\_\_ **Phone:** \_\_\_\_\_

**Patient Status:** New to Therapy \_\_\_\_\_ Continuing Therapy \_\_\_\_\_ **Next Treatment Date:** \_\_\_\_\_

**INSURANCE INFORMATION:** Please attach a copy of insurance cards (front and back).

**Medical Information**

**Patient Weight:** \_\_\_\_\_ lbs. **Allergies:** \_\_\_\_\_

**Diagnosis:** Crohn's disease \_\_\_\_\_ Ulcerative colitis \_\_\_\_\_ Rheumatoid arthritis \_\_\_\_\_ Ankylosing spondylitis \_\_\_\_\_

**ICD-10:** \_\_\_\_\_ Psoriasis \_\_\_\_\_ Other: \_\_\_\_\_

**Therapy Order**

**Infliximab:** (choose one)  Infuse infliximab **OR** infliximab biosimilar as required by patient's insurance  
 \*\*Preferred product to be determine after benefits investigation (noted below)  
 Do not substitute. Infuse the following infliximab product: \_\_\_\_\_

**Dose:** \_\_\_\_\_ mg/kg

**Frequency:** weeks 0, 2 and 6, then every 8 weeks (initial start) x1 year  
 Every \_\_\_\_\_ weeks (maintenance dose) x1 year  
 Other: \_\_\_\_\_

**Premedication orders:** Tylenol 1000 mg 500 mg PO, please choose 1 antihistamine:  
 Diphenhydramine 25 mg PO Loratadine 10 mg PO Cetirizine 10 mg PO Quzyttir 10 mg IVP

**Additional premedications:** Solu-Medrol \_\_\_\_\_ mg IVP Solu-Cortef \_\_\_\_\_ mg IVP Other: \_\_\_\_\_

**Lab orders:** \_\_\_\_\_ **Frequency:** Every infusion Other: \_\_\_\_\_  
 Yearly TB testing QFT (optional) Required labs to be drawn by: Hy-Vee Health Referring Physician

**Anaphylactic reaction orders:**

- Epinephrine (based on patient weight)
  - >30kg (>66lbs): EpiPen 0.3 mg or compounded syringe IM or Sub-Q; may repeat in 5-10 minutes x1
  - 15-30kg (33-66lbs): EpiPen Jr. 0.15 mg or compounded syringe IM or Sub-Q; may repeat in 5-10 minutes x1
- Diphenhydramine: Administer 25-50 mg orally OR IV (adult)
- NS 0.9% 500 mL IV bolus as needed (adult)
- Refer to physician order or institutional protocol for pediatric dosing

**Flush orders:** NS 1-20 mL pre/post infusion PRN and Heparin 10U/mL or 100U/mL per protocol as indicated PRN

**\*For Hy-Vee Health Use Only**

**Drug/Brand Selection:** \_\_\_\_\_

**Physician Information**

By signing this form and utilizing our services, you are authorizing *Hy-Vee Health* and its employees to serve as your prior authorization and specialty pharmacy designated agent in dealing with medical and prescription insurance companies.

**Provider Name:** \_\_\_\_\_ **Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**Provider NPI:** \_\_\_\_\_ **Phone:** \_\_\_\_\_ **Fax:** \_\_\_\_\_ **Contact Person:** \_\_\_\_\_

Opt out of Hy-Vee Health selecting site of care (if checked, please list site of care): \_\_\_\_\_

**Service Areas**

Des Moines, IA West Des Moines, IA Chicago, IL Omaha, NE Buffalo, NY Dallas, TX Phoenix, AZ Other \_\_\_\_\_

HY-VEEHEALTHINFUSION.COM

**IMPORTANT NOTICE:** This fax is intended to be delivered only to the named addressee and contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.



# COMPREHENSIVE SUPPORT FOR INFLIXIMAB THERAPIES

## Patient Information

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_

## Required Documentation for Referral Processing & Insurance Approval

Include signed and completed order (MD/prescriber to complete page 1)

Include patient demographic information and insurance information

Include patient's medication list

Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits or contraindications to conventional therapy

Has the patient had a documented contraindication/intolerance or failed trial of a DMARD, NSAID or conventional therapy (i.e., MTX, Leflunomide)?

Yes No

If yes, which drug(s)? \_\_\_\_\_

Does the patient have a contraindication/intolerance or failed trial to at least 1 biologic (i.e., Humira, Enbrel, Stelara, Cimzia)?

Yes No

If yes, which drug(s)? \_\_\_\_\_

If psoriasis diagnosis, percent of body surface (BSA) involved: \_\_\_\_\_ %

Include labs and/or test results to support diagnosis

If applicable – Last known biological therapy: \_\_\_\_\_ and last date received: \_\_\_\_\_. If patient is switching to biologic therapies, please perform a washout period of \_\_\_\_\_ weeks prior to starting infliximab.

Other Medical Necessity: \_\_\_\_\_

## Required Prescreening

**TB screening test completed within 12 months – attach results**

**Positive Negative**

**Hepatitis B screening test completed. This includes Hepatitis B antigen and Hepatitis B core antibody total (not IgM) – attach results**

**Positive Negative**

\*If TB or Hepatitis B results are positive, please provide documentation of treatment or medical clearance, and a negative CXR (TB+).

Hy-Vee Health will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

HY-VEEHEALTHINFUSION.COM

**IMPORTANT NOTICE:** This fax is intended to be delivered only to the named addressee and contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.